b-cells

Documents about b-cells

• Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma#451461ClinicalTrials.gov
• CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma#877348ClinicalTrials.gov
• Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide#877742ClinicalTrials.gov
• Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells#369846ClinicalTrials.gov
• Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells#805638ClinicalTrials.gov
• Impaired suppressive effect of FoxP3 regulatory T cells on B cells in multiple sclerosis#212949Europe PMC
• A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas#856853ClinicalTrials.gov
• Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells#148768ClinicalTrials.gov
• CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL#889283ClinicalTrials.gov
• CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies#878848ClinicalTrials.gov
• Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation#906982ClinicalTrials.gov
• Dynamics of memory B cells and plasmablasts in healthy individuals#153767HAL (France)
• Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis#911150ClinicalTrials.gov
• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies#279509ClinicalTrials.gov
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies#846631ClinicalTrials.gov
• Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma#141101ClinicalTrials.gov
• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies#435725ClinicalTrials.gov
• Extracellular vesicles from glycolytic mesenchymal stromal cells restrain arthritis progression via IL-10–Producing T and B cells#274304HAL (France)
• Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia#28330ClinicalTrials.gov
• Elranatamab: A novel B-cell maturation T-cell engager#642684Europe PMC
• SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism#935826Repositorio de Universidad Autónoma de Chile.
• A single Musashi gene allele is sufficient to maintain mouse photoreceptor cells.#189912NCBI PubMed Central
• CD1a-Mediated Presentation of Canonical Microbial Peptides to T Cells#266268bioRxiv / medRxiv
• The pathogenic role of double-negative B cells in autoimmune diseases.#446101NCBI PubMed Central
• Data Management and Sharing Plan for: Function of IL35+ B cells in pancreatic cancer#649108UNC Dataverse Dataverse OAI Archive
• Phase 1b/2a in SLE With Budoputug#894260ClinicalTrials.gov
• In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus#238950HAL (France)
• Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia#909912ClinicalTrials.gov
• <b><i>Mycoplasma pneumoniae</i></b><b> CARDS protein induces host cholesterol remodeling to activate type I interferon signaling in airway epithelial cells</b>#420140Figshare
• Association of Polygenic Risk Scores of the Different B Cell Malignancies with the Risk of B Cell Acute Lymphoblastic Leukemia: Case-Control Study#824195Scholar Commons
• B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy#4577Europe PMC
• Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma#184974Dipòsit Digital de la Universitat de Barcelona
• Development and Characterization of Affinity-Maturated Nanobodies Targeting B-Lymphocyte Antigen Cd19#195203İzmir Yüksek Teknoloji Enstitüsü
• Dysregulated BCR repertoire and metabolic state of HBsAg-specific B cells in chronic hepatitis B revealed by integrated single-cell analysis.#449979NCBI PubMed Central
• Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine#807743ClinicalTrials.gov
• Relmacabtagene Autoleucel in Hematologic Malignancies#832124ClinicalTrials.gov
• Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma#850644ClinicalTrials.gov
• Maintenance of immune tolerance during aging requires competitive expansion of memory phenotype regulatory T cells#373549bioRxiv / medRxiv
• Robot-Assisted Study of a Near-Infrared Dye in Perovskite Solar Cells.#388757NCBI PubMed Central
• Atlas of human gut-associated lymphoid tissue reveals immunomodulatory interactions of B cells#404583PubMed Central
• Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL#481773ClinicalTrials.gov
• Identification of circulating MOG-specific B cells in patients with MOG antibodies#955708Koc University Digital Collections
• Hippo signaling regulates cuticle pigmentation and dopamine metabolism in <i>Drosophila</i>#477073PLOS
• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies#136335ClinicalTrials.gov
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies#217035ClinicalTrials.gov
• Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma#140978ClinicalTrials.gov
• Defective B cell tolerance in SLE lymph nodes underpins VH4-34 "clonal damnation" and PD-1+TOX+ autoreactive B cells expansion.#282953bioRxiv / medRxiv
• Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma#915980ClinicalTrials.gov
• Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.#318769Dipòsit Digital de la Universitat de Barcelona
• Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia#125823ClinicalTrials.gov